Clinical Pharmacology and Therapeutics Pharmacology
Operationalizing <scp>ICH E17</scp> in Multiregional Clinical Trials: A Practical Roadmap for <scp>AI</scp> ‐Enabled and Quantitative Methods as Enabling Tools
Abstract
ICH E17 harmonized the design and interpretation of multiregional clinical trials (MRCTs), yet almost a decade after adoption, its operationalization remains inconsistent across several areas: regional definition, assessment of regional heterogeneity, evaluation of intrinsic and extrinsic factors, pooling, bridging and extrapolation, and integration of real‐world data. This White Paper offers a practical roadmap for operationalizing ICH E17 across the MRCT lifecycle (planning, conduct, and submission) in which artificial intelligence (AI), pharmacometric, and biostatistical methods are treated as enabling tools rather than as the primary subject. In this paper, for each decision point, we frame a context of use, decision consequence, validation expectation, bias assessment, documentation need, and likely regulatory engagement pathway, and we distinguish approaches that are usable today for operational support from those that may provide supportive evidence with appropriate validation and those that remain exploratory. We do not propose specific regulatory recommendations; rather, we intend this roadmap to stimulate cross‐stakeholder discussion and the accumulation of shared, well‐documented use cases that could, in time, inform future implementation‐oriented guidance.